Drug Profile
Research programme: chelating agents - PALUMED
Alternative Names: PA 1637Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator PALUMED
- Class
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in France
- 04 Feb 2011 Preclinical development is ongoing in France
- 26 Feb 2007 Preclinical trials in Alzheimer's disease in France (unspecified route)